Related Experiment Video
Updated: May 5, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
190
Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report
Oncotarget
|May 4, 2026
Summary
This study details a rare gastrointestinal stromal tumor (GIST) with both KIT and SDHC mutations. The patient responded well to imatinib therapy, suggesting KIT signaling drove the GIST
Area of Science:
- Oncology
- Gastroenterology
- Molecular Pathology
Background:
- Gastrointestinal stromal tumors (GISTs) are classified by molecular alterations, typically involving KIT or PDGFRA mutations, predicting imatinib sensitivity.
- Succinate dehydrogenase (SDH)-deficient GISTs lack these mutations and are generally resistant to imatinib.
- These molecular subtypes are usually considered mutually exclusive.
More Related Videos
09:16Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
Published on: February 5, 2018
5.6K
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
11.9K